Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vertex claims "time to be profitable", as it assembles sales force ahead of FDA decision on telaprevir

This article was originally published in Scrip

Executive Summary

With increased investment in building out a US commercial infrastructure and higher R&D spending, it was not surprising that Vertex reported that its loss widened in 2010. The company is building up its US commercial organisation in anticipation of a US FDA decision on 23 May on its lead drug candidate, telaprevir, as a potential treatment for hepatitis C.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts